Covid-19 patients at high risk of hospitalisation or those with severe disease should be given a combination of two antibody treatments, according to latest World Health Organization guidelines published in The BMJ on Friday.
 The WHO Guideline Development Group (GDG) panel recommends treatment combining casirivimab and imdevimab for two specific groups of patients with Covid-19.
The first are patients with non-severe Covid-19 who are at highest risk of hospitalisation and the second are those with severe or critical Covid-19 who are seronegative, meaning they have not mounted their own antibody response to Covid-19.

Covid-19 patients at high risk of hospitalisation or those with severe disease should be given a combination of two antibody treatments, according to latest World Health Organization guidelines published in The BMJ on Friday.
 The WHO Guideline Development Group (GDG) panel recommends treatment combining casirivimab and imdevimab for two specific groups of patients with Covid-19.
The first are patients with non-severe Covid-19 who are at highest risk of hospitalisation and the second are those with severe or critical Covid-19 who are seronegative, meaning they have not mounted their own antibody response to Covid-19.